جست‌وجوی استاد و پژوهشگر

Kristian Helinمشاهده پروفایل

استاد

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

Weiping Tangمشاهده پروفایل

استاد

• Targeted Protein Degradation
• PROTACs
• Medicinal Chemistry
• +۵ مورد دیگر

Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.

• Immunology
• Genomics
• Multiomics Analysis
• +۳ مورد دیگر

Calliope Dendrou is an Associate Professor in Clinical Pathology and Inflammation at the Kennedy Institute of Rheumatology (KIR), University of Oxford, leading the Immune Disease Multiomics Laboratory. She previously held a Wellcome & Royal Society Sir Henry Dale Fellowship at the University of Oxford’s Centre for Human Genetics before joining KIR in 2023. Her research focuses on immune disease mechanisms using multiomics approaches, including genomic profiling to identify therapeutic targets across tissues and immune-mediated diseases. She co-leads large-scale projects like the Oxford-J&J Cartography Consortium and the Chan Zuckerberg Initiative’s LEGACY Network, and teaches on the MSc in Genomic Medicine program. Educational Background: BSc (Biology, Imperial College London, 2005; Forbes Memorial Medal Winner); PhD in Infection & Immunity (University of Cambridge, 2010). Postdoctoral training at the Weatherall Institute of Molecular Medicine under Prof. Lars Fugger. Research interests include immunogenetics, cytokine signaling pathways, drug repositioning, and cross-disease pathophysiology. Her work integrates single-cell and spatial transcriptomics to dissect immune-cell interactions in diseases like rheumatoid arthritis, inflammatory bowel disease, and celiac disease. Recent articles highlight her contributions to understanding vaccine adjuvant responses, Th17 cell roles in spondyloarthritis, and immune-epithelial networks in celiac disease. Collaborations emphasize multi-omic data analysis (e.g., Panpipes pipeline) and translational studies toward precision medicine. Awards: Forbes Memorial Medal (BSc), Wellcome & Royal Society Sir Henry Dale Fellowship. Leadership roles include Equality, Diversity, and Inclusion Champion and 'Single-Cell & Spatial Omics for Precision Medicine' Module Lead. Lab & Teams: Immune Disease Multiomics Lab at KIR. Active in collaborative initiatives such as the LEGACY Network, focusing on large-scale immune profiling in ancestrally diverse populations.

Réka Albertمشاهده پروفایل

استاد

• Biological Physics
• Network Science
• Systems Biology
• +۳ مورد دیگر

Réka Albert is a Distinguished Professor of Physics at Pennsylvania State University, affiliated with the Eberly College of Science. Her research focuses on the application of network science to biological systems, including signal transduction networks, ecological interactions, and cancer systems biology. She holds editorial roles at npj Systems Biology and Applications , IET Systems Biology , and Bulletin of Mathematical Biology . Education: Ph.D. in Physics from the University of Notre Dame (2001), M.S. and B.S. from Babeș-Bolyai University, Romania (1995-1996). Research Interests: Modeling complex systems using network theory; Boolean network analysis of biological pathways; ecological community dynamics; systems-level understanding of disease mechanisms (e.g., cancer, AML). Her work bridges theoretical physics, computational biology, and experimental data to predict system behavior and therapeutic strategies. Awards: External member of the Hungarian Academy of Sciences (2016), APS Maria Goeppert-Mayer Award (2011), NSF CAREER Award (2007), and Alfred P. Sloan Fellowship (2004). Grants/Support: NSF awards (MCB 1715826, IIS 1814405), ARO MURI on hyperuniform systems, and collaborations with biologists like Sarah Assmann (plant signaling) and Katriona Shea (ecology). Labs/Teams: Leads a multidisciplinary research group at Penn State, mentoring over 20 PhD alumni and current students like Eli Newby and Fatemeh Nasrollahi. Active in developing tools like pystablemotifs for Boolean network analysis.

Sachdev Sidhuمشاهده پروفایل

استاد پژوهشی

• Synthetic Antibodies
• Protein Engineering
• Biotechnology
• +۵ مورد دیگر

Sachdev Sidhu is a Research Professor and Entrepreneur in Residence at the University of Waterloo. His research focuses on synthetic antibodies, protein engineering, and biotechnological applications. He leads efforts in developing novel therapeutic antibodies, engineered protein systems, and molecular tools for biomedical research. His work spans cancer therapy, viral infection countermeasures, and regenerative medicine. Sidhu is also involved in translational research, bridging academic discoveries with commercial applications through entrepreneurial ventures. Key research interests include synthetic antibody libraries, CAR T-cell engineering, ubiquitin-based therapeutics, and phage display technologies. He has contributed to advancements in targeted therapies for glioblastoma, leukemia, and ocular diseases. His team develops innovative methods for protein design, such as engineered ubiquitin variants and modular antibody architectures. Publications highlight breakthroughs in antibody-based treatments, including synNotch CAR T cells for glioblastoma and neutralizing antibodies against SARS-CoV-2. His work integrates structural biology, molecular biology, and computational approaches to address complex biomedical challenges. Sidhu collaborates with industry partners to advance technologies into clinical and commercial settings.

Waldemar Kolanusمشاهده پروفایل

استاد

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +۴ مورد دیگر

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

Aaron Loganمشاهده پروفایل

دانشیار بالینی

• Hematology
• Oncology
• Immunology
• +۳ مورد دیگر

Dr. Aaron Logan is a Clinical Associate Professor of Medicine at the University of California, San Francisco (UCSF). He specializes in the clinical management of acute leukemias, myelodysplastic syndromes, aplastic anemia, and hemophagocytic lymphohistiocytosis. Additionally, he directs a research laboratory focused on immune repertoire profiling following hematopoietic cell transplantation. MD and PhD in Molecular Microbiology and Immunology from Keck School of Medicine (2006) MPhil in History of Medicine from University of Cambridge (2005) Internal Medicine Residency and Hematology Fellowship at Stanford University Dr. Logan's research explores clonotypic diversity in B and T lymphocyte repertoires, utilizing techniques like TREC/KREC quantification, high-throughput sequencing, and mixed lymphocyte reactions. His work has significant applications in tracking immune responses post-transplantation and quantifying measurable residual disease in lymphoid cancers. Notable scientific contributions include advancements in CAR T-cell therapy and immune profiling for blood malignancies. His publications cover topics in B-cell ALL , AML , and measurable residual disease monitoring. 2020 - UCSF Hematology-Oncology Fellowship Teaching Award 2011 - ASH Abstract Award and Research Training Award 2003 - Keck School of Medicine Outstanding Teaching Award As director of the UCSF Hematologic Malignancies Tissue Bank, Dr. Logan provides deidentified patient samples to support collaborative research on blood cancers and post-transplantation immune dynamics.

Ross L. Levineمشاهده پروفایل

استاد

• Hematology
• Oncology
• Genetics
• +۴ مورد دیگر

Ross L. Levine, MD, is a distinguished Professor and Physician-Scientist at Memorial Sloan Kettering Cancer Center (MSKCC), holding the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes (MDS). As Senior Vice President of Memorial Hospital’s Translational Research division, he leads groundbreaking work in hematologic malignancies, particularly leukemia and myeloproliferative neoplasms (MPNs). His research integrates clinical care with genomic and molecular studies to develop targeted therapies. Levine received his MD from Johns Hopkins University School of Medicine, followed by residency in Internal Medicine at Massachusetts General Hospital and fellowship in Hematology/Oncology at Dana-Farber Cancer Institute. Education: MD, Johns Hopkins University School of Medicine Residencies: Internal Medicine, Massachusetts General Hospital Fellowships: Hematology/Medical Oncology, Dana-Farber Cancer Institute Levine’s research focuses on the genetic and epigenetic drivers of myeloid cancers, including JAK-STAT pathway mutations in MPNs and AML. His team explores therapeutic strategies targeting CXCL8/CXCR2 signaling and clonal hematopoiesis. Key contributions include identifying JAK2 mutations in MPNs and advancing single-cell mutation analysis for clonal evolution studies. His clinical expertise includes treating patients with acute myeloid leukemia (AML), polycythemia vera, and myelofibrosis, performing bone marrow biopsies, and leading clinical trials for targeted therapies. Levine has pioneered translational research programs linking lab discoveries to patient care, emphasizing precision medicine. Awards & Honors: Pershing Square Sohn Prize (2014), Howard Hughes Medical Institute Early Career Award (2007), and multiple Leukemia & Lymphoma Society accolades. He holds leadership roles in professional societies, including co-chairing the American Society of Hematology’s 2016 Scientific Program. Levine’s lab, part of the Human Oncology & Pathogenesis Program (HOPP), collaborates with institutions globally. His work has been published in high-impact journals like Cancer Cell , Nature , and Blood , advancing understanding of cancer genetics and therapeutic innovation.

John A. Copland, IIIمشاهده پروفایل

استاد

• Cancer Biology
• Molecular Carcinogenesis
• Translational Research
• +۳ مورد دیگر

Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models

Laura Soltمشاهده پروفایل

دانشیار

• Autoimmune Disease
• Cancer Immunotherapy
• Immunometabolism
• +۵ مورد دیگر

Laura Solt, Ph.D. is an Associate Professor in the Department of Immunology and Microbiology at the Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida. She also serves as Associate Dean of the Skaggs Graduate School of Chemical and Biological Sciences. Dr. Solt began her independent research career at Scripps Florida in 2013 and has established herself as a leading researcher in nuclear receptor biology within the immune system. Her research focuses on understanding the biologically relevant roles of nuclear receptors, particularly RORα and REV-ERBs, in the immune system with emphasis on TH17 cell development and autoimmune disease. Her lab employs a multidisciplinary approach combining molecular biology, genetic techniques, and chemical biology coupled with mouse models of autoimmunity and chronic inflammation. Dr. Solt's laboratory has made significant contributions to understanding how nuclear receptors regulate immune cell function, particularly in TH17-mediated inflammation. Her work has demonstrated roles for RORα and REV-ERBs in TH17 cell development and has developed synthetic ligands to these receptors for potential therapeutic applications in autoimmune diseases. Her extensive publication record shows a clear trajectory of research focused on nuclear receptor signaling in immunity, with recent work expanding into applications for cancer immunotherapy, neuroimmunology, and metabolic aspects of immune cell function. Her articles demonstrate expertise in both basic nuclear receptor mechanisms and translational applications. Ruth L. Kirschstein National Research Service Awards (2010-2013) Dr. Solt actively mentors graduate students including Adrianna Wilson (recipient of NIDDK F31 and Scheller Graduate Student Fellowship) and Sarah Mosure (recipient of NIH NRSA F31 award and Wendy Havran award). Her laboratory receives substantial funding from multiple NIH institutes (NIDDK, NCI, NIAID, NIGMS) as well as the Crohn's & Colitis Foundation. Current research directions include investigating the roles of NR2F6 in TH17 cells, exploring RORα function in CD8 T cells, and developing novel nuclear receptor modulators for therapeutic applications.

• Statistical Methods in Biomedical Research
• Biomarker Analysis
• Clinical Trial Design
• +۷ مورد دیگر

Todd A. Alonzo is a Professor of Research in the Department of Preventive Medicine at the University of Southern California . As Group Statistician for the Children's Oncology Group , he focuses on statistical methods for biomarker analysis, medical diagnostic testing, and clinical trial design in pediatric acute myeloid leukemia (AML). Education: B.S. in Statistics, California State Polytechnic University (1994) MS and PhD in Biostatistics, University of Washington (1997, 2000) Research Interests include: Development of statistical frameworks for diagnostic accuracy Genomic and proteomic profiling in AML Pharmacogenomic score systems for chemotherapy response Non-inferiority trial design in low-event-rate settings Health disparities in pediatric oncology Scientific Awards : Fellow, American Statistical Association (2018) Outstanding Teacher Award, International Society for Magnetic Resonance in Medicine (2017) NIH Predoctoral Cardiovascular Biostatistics Training Grant (1995) ENAR Biometrics Society Distinguished Student Paper Award (1999) WNAR Biometrics Society Best Student Oral Presentation (1999) Leadership & Service includes editorial board memberships (Biometrics, Pediatric Blood & Cancer, Biometrical Journal), reviewer for 30+ scientific journals, and roles on multiple Data Safety and Monitoring Boards. He served as President of the International Biometric Society Western Northern America Region (WNAR) in 2009.

Peter A. Jonesمشاهده پروفایل

استاد

• Epigenetics
• DNA methylation
• Cancer epigenetics
• +۷ مورد دیگر

Peter A. Jones is President and Chief Scientific Officer at the Van Andel Institute (VAI) in Grand Rapids, Michigan, where he leads the Department of Epigenetics. He previously served as Director of the USC Norris Comprehensive Cancer Center from 1993 to 2011 and has been a central figure in advancing epigenetics research, particularly in cancer. His laboratory investigates DNA methylation, chromatin dynamics, and epigenetic therapies. Research Interests: Dr. Jones's work centers on epigenetic mechanisms in cancer, including DNA methylation, histone modifications, nucleosome positioning, and the therapeutic potential of epigenetic drugs. His research has pioneered the use of DNA methylation inhibitors like 5-azacytidine and explored viral mimicry as a mechanism for immune activation in cancer. He also studies transposable elements and their role in gene regulation and immune response. Publication Trends: His recent publications (2021–2024) reveal a strong focus on the interplay between epigenetics and immunotherapy, particularly how DNA methyltransferase inhibitors (DNMTi) induce viral mimicry, enhance immune recognition, and improve responses to checkpoint blockade. Studies span hematological malignancies, solid tumors, and T cell biology, with frequent collaboration with Stephen Baylin and others. Scientific Awards: Member, National Academy of Sciences Member, National Academy of Medicine Fellow, AACR Academy Fellow, AAAS Fellow, American Academy of Arts and Sciences Kirk A. Landon Award for Basic Cancer Research (2009) Medal of Honor, American Cancer Society (2011) Outstanding Investigator Grant, NCI Harvey Prize (2024) Advising and Grants: Dr. Jones mentors multiple postdoctoral fellows, graduate students, and research scientists. His lab is supported by major grants, including the VAI-SU2C Epigenetics Dream Team, which has launched 15 clinical trials. He has received sustained funding from the National Cancer Institute and collaborates with institutions worldwide to advance epigenetic therapies. Labs and Teams: He leads the Peter Jones Laboratory at VAI, a multidisciplinary team investigating epigenetic regulation in cancer. The lab includes computational biologists, clinical researchers, and molecular biologists, working on both basic mechanisms and translational applications. The team is part of larger collaborative initiatives such as the VAI-SU2C Epigenetics Dream Team and the International Linked Clinical Trials Program.

Joshua D. Rabinowitzمشاهده پروفایل

استاد

• Cellular Metabolism
• Metabolomics
• Systems Biology
• +۵ مورد دیگر

Joshua D. Rabinowitz is a Professor of Chemistry and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where he also serves as Director of the Ludwig Princeton Branch. His research focuses on achieving a quantitative, comprehensive understanding of cellular metabolism, with applications in both basic science and medical research. Dr. Rabinowitz's research interests span multiple areas of metabolism and systems biology: Quantitative analysis of metabolic networks and regulation Metabolomics and measurement of metabolite concentrations and fluxes Cancer cell metabolism and therapeutic targeting Metabolic regulation in microbes (E. coli, Saccharomyces cerevisiae) Biofuel production (focusing on Clostridium acetobutylicum) Metabolic impact of pathogen infection (viral infection of human cells) His laboratory has developed innovative methods for measuring cellular metabolites using state-of-the-art mass spectrometry technology and approaches for quantitating metabolic fluxes through isotope-labeling data interpretation. Analysis of recent publications reveals a strong focus on NAD+ metabolism, cancer metabolism, metabolic adaptations in disease states, and the intersection of metabolism with immunology and neuroscience, particularly in areas like T cell metabolism, Alzheimer's disease, and cardiac function. Dr. Rabinowitz has received recognition as a Highly Cited Researcher by Web of Science, indicating significant impact in his field. He advises several graduate students and has mentored numerous alumni, including Michel I. Nofal, Edmundo Leiva III, and Sean Hackett. His research is supported by multiple programs including NIH NHGRI Training Program and QCB Graduate Program. The Rabinowitz Lab operates at the intersection of chemistry, biology, and computational science, with all projects involving a mix of biological experiments, metabolomics, and computation to achieve their goal of a holistic understanding of cellular metabolism.

• Immuno-oncology
• Cancer Immunology
• Tumor Microenvironment
• +۳ مورد دیگر

Kurt Schalper, MD, PhD is an Associate Professor of Pathology at Yale School of Medicine and Director of the Translational Immuno-Oncology Laboratory (T.I.L.) at Yale Cancer Center. His primary appointment is in the Department of Pathology with secondary appointments in Medical Oncology and Hematology. Dr. Schalper maintains affiliations with multiple cancer research entities including the Cancer Immunology Program, Yale Center for Immuno-Oncology, and the Yale Combined Program in the Biological and Biomedical Sciences (BBS). Dr. Schalper trained as a cell biologist and surgical pathologist, completing his MD at San Sebastian University (2003) and PhD at Universidad Catolica de Chile (2008). His postdoctoral work at Yale focused on developing quantitative strategies to measure immunotherapy-related biomarkers in immune cells and cancer tissues. His research centers on understanding the immunobiology of human solid tumors, particularly lung cancer, with emphasis on immune evasion mechanisms, tumor microenvironment dynamics, and biomarker development for immunotherapy response prediction. Current scientific interests include tumor immune heterogeneity, editing, and the role of specific tumor antigens and immune evasion pathways in lung malignancies. Analysis of Dr. Schalper's recent publications reveals a strong focus on immuno-oncology, particularly in lung cancer. His work spans biomarker development, mechanisms of immunotherapy resistance, tumor microenvironment characterization, and clinical translation of immunotherapeutic approaches. Notable themes include the investigation of KEAP1/STK11-related resistance, IL-4 mediated immune evasion, and strategies to overcome immunotherapy resistance through combination approaches. Dr. Schalper collaborates extensively with Yale researchers, particularly with Dr. David Rimm (57 common publications), Dr. Roy S. Herbst (35 common publications), Dr. Scott Gettinger (14 common publications), and Dr. Sarah Goldberg (12 common publications). His work appears in high-impact journals including Nature, Journal of Clinical Investigation, and Nature Reviews Clinical Oncology. As Director of the Translational Immuno-Oncology Laboratory, Dr. Schalper leads efforts to produce and support high-quality translational research in immuno-oncology through standardized biomarker analyses and integration with Yale resources. His laboratory focuses on developing quantitative methods for immunotherapy biomarker assessment and understanding mechanisms of response and resistance to cancer immunotherapies.

• Hematopathology
• Molecular Diagnostics
• Flow Cytometry
• +۷ مورد دیگر

Alexa Siddon, MD, is an Assistant Professor in the Department of Laboratory Medicine at Yale School of Medicine, with secondary appointments in Pathology. She serves as Hematopathology Fellowship Director, Director of the Molecular Diagnostics Laboratory, Director of Flow Cytometry, and Associate Director of the Hematology Laboratory. She is also affiliated with the Yale Cancer Center, Clinical Flow Cytometry Laboratory, and the Hematopathology Laboratory at the Veteran Affairs Connecticut Healthcare System. Dr. Siddon's research focuses on hematopathology, particularly myeloid malignancies, acute leukemias, and post-transplant monitoring. Her work integrates molecular diagnostics, flow cytometry, and genomic analysis to improve patient diagnosis and outcomes. She has co-authored over 10 peer-reviewed articles in recent years, frequently collaborating with leading hematologists and pathologists such as Christopher Tormey, Henry Rinder, and Rory Shallis. Her publications reveal a strong trend in translational research, emphasizing the clinical implications of genetic mutations (e.g., TP53, NPM1, IDH1/2), chimerism testing post-transplant, and immunophenotypic characterization of hematologic malignancies. The research spans disciplines including oncology, molecular biology, immunology, and clinical pathology, with a clear focus on precision diagnostics and prognostic modeling. Scientific Awards: ASCP Distinguished Educator Award Paul J. Strandjord Young Investigator Award Donald H. Buchholz Research Prize Dr. Siddon is actively involved in medical education, directing fellowship programs and mentoring trainees. She has no reported grants listed in the text, but her leadership in diagnostic laboratories and active publication record suggest ongoing research funding. She is not part-time, not retired, and remains a current, active faculty member. She is affiliated with multiple research entities including the Cancer Immunology Center, Center for Biomedical Data Science, and the Yale Cancer Center, contributing to interdisciplinary teams focused on hematologic malignancies and diagnostic innovation.